Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
Purple Biotech reported Q1 2026 results with a net loss of $0.1 million, driven by $2.2 million in non-cash finance income from warrant revaluation that offset a $2.2 million operating loss. The company holds $6.4 million in cash, providing a runway into 2027, while R&D expenses rose to $1.2 million due to CMC activities for its lead asset IM1240.
Key figures
- Eps
- 0.09
- Revenue
- 0
- Net loss
- 89000
- Ga expenses
- 1021000
- Rd expenses
- 1230000
- Cash position
- 6400000
- Operating loss
- 2251000
- Adjusted net loss
- 2169000
- Finance income net
- 2162000
- Adjusted operating loss
- 2158000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.